TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01094665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Targeted Focal Laser Thermal Therapy
Description: A 980nm wavelength diode laser will be fired for up to 30 minutes. Temperature probes will be inserted to ensure that the local temperature does not exceed 55 degrees Celsius for more than 5 minutes.
Study: NCT02717507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01799993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin Inhalation Solution (BAY41-6551)
Description: 400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aerosolized Placebo
Description: Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
Study: NCT02823171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: 400 mg Pacritinib P3CT
Description: 400-mg oral dose of pacritinib P3CT (reference) formulation capsules
Study: NCT02717507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02823171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: 400 mg Pacritinib P3CT
Description: 400-mg oral dose of pacritinib P3CT (reference) formulation capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: 400 mg of pacritinib FMI
Description: 400-mg oral dose of pacritinib FMI (test) formulation capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: 400 mg of pacritinib FMI
Description: 400-mg oral dose of pacritinib FMI (test) formulation capsules
Study: NCT01057888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autodialer
Description: Autodialer telephone calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letters
Description: Mailed reminder letters
Study: NCT02877745

Intervention type: OTHER
Intervention: Stratification, no intervention

Intervention type: OTHER
Intervention: Stratification, no intervention
Study: NCT03401411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Survey of 15 fictional patient case scenarios to be assessed by participant using the standard prioritization or modified SCCMP to prioritize each patient scenario into one of a 5-point likert-scale categories for ICU admission. SCCMP scale categorized as 1-Critically ill to 4-Less likely to require ICU.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Survey of 15 fictional patient case scenarios to be assessed by participant using the standard prioritization or modified SCCMP to prioritize each patient scenario into one of a 5-point likert-scale categories for ICU admission. SCCMP scale categorized as 1-Critically ill to 4-Less likely to require ICU.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Algorithm-based Triage Tool
Description: Newly designed flowchart-based triage guide to prioritize each patient case scenario into one of the 5-point likert-scale categories, used in conjunction with SCCMP for ICU admission.
Study: NCT03887468

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EvoCit
Description: hemodialysis using the combination of the Evodial dialyzer with a citrate enriched dialysate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EvoHep
Description: hemodialysis using the combination of the Evodial dialyzer with a conventional bicarbonate based dialysate and systemic anticoagulation using unfractionated heparin
Study: NCT00295750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide 7.5 mg
Description: Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
Study: NCT01204151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: discrete-trial training
Study: NCT02714439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine
Description: Proflavine 0.01% applied to the cervix before high-resolution microendoscopy imaging procedure performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscopy (HRME)
Description: High-resolution microendoscopy imaging procedure performed after colposcopy exam. Standard colposcopy procedure will then continue. Entire HRME imaging procedure should add less than 10 minutes to the standard colposcopy exam.
Study: NCT00450086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 9 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: 3 g per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 g per day
Study: NCT01840540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arterial infusion of autologous mesenchymal stem cells
Study: NCT04114981

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Single Fraction Stereotactic Radiosurgery
Description: Undergo SSRS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiosurgery
Description: Undergo FSRS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02679690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Dietary Sodium Education
Description: Standard dietary education for sodium restricted diets for patients with heart failure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Color-Coded Cue Cards
Description: The use of a color-coded cue card to designate ranges of acceptable sodium content of food for comparison to labels while grocery shopping.
Study: NCT04499248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-193408 SR
Description: An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-193408 SR
Description: An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-193408 SR
Description: An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-193408 SR
Description: An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.
Study: NCT00698178

Intervention type: OTHER
Intervention: Anthropometric measurements
Description: All patients undergo anthropometric measurements to record body weight, body height and waist circumference on the day of enrollment
Study: NCT04499248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumigan
Description: Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumigan
Description: Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumigan
Description: Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumigan
Description: Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost
Study: NCT02163811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VETPALS
Description: VETPALS is an adaption of an empirically supported self-management program, PALS (Promoting Amputee Life Skills). The PALS program demonstrated improved physical and psychosocial functioning when delivered in community-based support groups for amputees, but this program has not been adapted for the needs of Veterans and implemented in the VA healthcare system.~VETPALS is a five session course for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA clinician in conjunction with a peer facilitator (Veteran with limb loss). Veterans receive all usual care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Education Support Program
Description: VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
Study: NCT04499248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumigan
Description: Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumigan
Description: Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Administration
Description: Needleless applicator contacting similar intracameral insertion location on eye as AGN-193408 SR.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Administration
Description: Needleless applicator contacting similar intracameral insertion location on eye as AGN-193408 SR.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumigan Vehicle
Description: Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 2.
Study: NCT00425659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: home sleep study
Description: different in algorithm arrangement for diagnosing sleep apnea

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: home CPAP titration (Autoset)
Description: continuous positive airway pressure device for treatment of sleep apnea

Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP
Description: usual practice
Study: NCT01787214

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Full dose
Description: 20% of daily energy needs supplied by walnuts

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Half dose
Description: 10% of daily energy needs supplied by walnuts

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control
Description: Walnut free meals
Study: NCT04499248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumigan Vehicle
Description: Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-193408 SR
Description: An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-193408 SR
Description: An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Administration
Description: Needleless applicator contacting similar insertion location on eye as AGN-193408 SR.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Administration
Description: Needleless applicator contacting similar insertion location on eye as AGN-193408 SR.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumigan Vehicle
Description: Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 3.
Study: NCT02098356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Bicarbonate
Description: Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
Study: NCT00948402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 1250 mg three times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive
Description: 30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.
Study: NCT02711150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLL Length Measured through US
Description: The PLL will be measured for each allocated position: EPD or Flexed Position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PLL Length Measured through US
Description: The PLL will be measured for each allocated position: EPD or Flexed Position
Study: NCT04499248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumigan Vehicle
Description: Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 3.
Study: NCT03943173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Given standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04121000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VIDEO ASSISTED THOTACOSOPIC SURGERY
Description: VATS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VIDEO ASSISTED THOTACOSOPIC SURGERY
Description: VATS
Study: NCT02357550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketone
Description: 3-OHB is infused intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Saline infusion.
Study: NCT01073020

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allergan Adjustable Gastric Band Surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group
Description: Intensive Medical Diabetes \& Weight Management (Why WAIT) - Band Group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB) Surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group
Description: Intensive Medical Diabetes \& Weight Management (Why WAIT) - Bypass Group
Study: NCT00003533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Metastatic Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02878291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine
Description: Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine
Description: Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
Study: NCT03910803

Intervention type: DRUG
Group type: OTHER
Intervention: Brodalumab
Description: Brodalumab is a human monoclonal IgG2κ antibody directed against human interleukin-17 receptor A (IL-17RA). It is expressed in a Chinese Hamster Ovary (CHO) cell line. Brodalumab is comprised of 1312 amino acids and has an estimated molecular mass of 144,000 Daltons.~Brodalumab Injection is a sterile, preservative-free, yellow solution, delivered via subcutaneous injection. . Each Brodalumab single dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8.
Study: NCT00882167

Intervention type: OTHER
Intervention: CineMRI
Description: CineMRI scan of the abdomen at 1.5 Tesla.
Study: NCT00313053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human mAb 216
Description: Two treatment courses of mAb infusion will be given, with the same dose of antibody administered on Day 0 and on Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.5 mg/m2/dose (max dose = 2 mg) IVP on weekly x 4 doses (Days 7, 14, 21, 28)
Study: NCT03932084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: During hospitalization:~1. Monitor subjects' blood glucose;~2. One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;~3. Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glucose fluctuation targeted intervention
Description: We set achieving goals for this intervention group (both A1c\<7% and LAGE\<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
Study: NCT02505776

Intervention type: DRUG
Intervention: Bimatoprost cutaneous solution 0.03%
Description: Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice.
Study: NCT05138198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet & Physical Activity
Description: At the beginning of each week (1-10), members were sent a text message introducing the week and providing the link to the week's website. This website includes downloadable material for this group with recipes and other important nutrition information, as well as the weekly topic information and informative video. After receiving the link to the website, members received a Qualtrics survey with a teach-back question related to the video and a goal-setting question related to the topics of the week. At the end of each week, members received another Qualtrics survey with a question regarding the goal of the past week.~* Visit 1: discuss Mediterranean diet score results from baseline and ways to improve~* Visit 2: discuss anti-inflammatory diet scorecard and ways to improve~* Discuss optimal dietary pattern (Med Diet pyramid handout)~* Personal dietary and exercise goals, reviewed baseline intake form, social support, self-efficacy, challenges, or barriers to achieving goals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: As part of usual care, members attended one-on-one monthly counseling sessions with the assigned dietitian and reviewed their current eating habits and physical activity, as well as other environmental factors that may be affecting their weight such as work, home environment, sleeping issues, and medications. After reviewing current practices, the RD provided medical nutrition therapy (MNT), a specific application of the Nutrition Care Process in clinical settings that focuses on the management of diseases (e.g. diabetes, heart disease, etc.). Specific dietary recommendations are based on the Bull's Eye Food Guide, used by Stony Brook University Hospital for outpatient nutrition counseling. Individuals in the standard care received more individualized calorie recommendations (usual care) than the Mediterranean diet group.
Study: NCT04248374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taste Intensity
Description: Taste intensity with and without sour adaptation
Study: NCT04670757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL409116
Description: IMP administration, tablets contain CPL409116 as an active ingredient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator
Study: NCT03246568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Nerve Denervation
Description: Bilateral renal denervation using a multi-polar radiofrequency ablation catheter (Symplicity™ Spyral Cather, Medtronic) in the right and left main, branch, and accessory renal arteries in vessels ranging in diameter between 3 and 8 mm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: PVI by cryo-balloon ablation without linear ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: PVI by cryo-balloon ablation without linear ablation